#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Considering the properties and biological role of silicon , we evaluated the effects of nutritional supplementation with silicon-enriched spirulina on vascular remodeling induced by hypertension in a SHR rat model .
2-1	14-25	Considering	_	_	_	_
2-2	26-29	the	abstract[2]	new[2]	_	_
2-3	30-40	properties	abstract[2]	new[2]	_	_
2-4	41-44	and	_	_	_	_
2-5	45-55	biological	abstract[3]	new[3]	coref	22-20[168_3]
2-6	56-60	role	abstract[3]	new[3]	_	_
2-7	61-63	of	abstract[3]	new[3]	_	_
2-8	64-71	silicon	abstract[3]|substance	new[3]|new	_	_
2-9	72-73	,	_	_	_	_
2-10	74-76	we	person	acc	ana	3-1
2-11	77-86	evaluated	_	_	_	_
2-12	87-90	the	abstract[6]	new[6]	coref	3-4[16_6]
2-13	91-98	effects	abstract[6]	new[6]	_	_
2-14	99-101	of	abstract[6]	new[6]	_	_
2-15	102-113	nutritional	abstract[6]|substance[7]	new[6]|new[7]	coref	6-6[37_7]
2-16	114-129	supplementation	abstract[6]|substance[7]	new[6]|new[7]	_	_
2-17	130-134	with	abstract[6]|substance[7]	new[6]|new[7]	_	_
2-18	135-151	silicon-enriched	abstract[6]|substance[7]|substance[8]	new[6]|new[7]|new[8]	_	_
2-19	152-161	spirulina	abstract[6]|substance[7]|substance[8]	new[6]|new[7]|new[8]	_	_
2-20	162-164	on	abstract[6]|substance[7]|substance[8]	new[6]|new[7]|new[8]	_	_
2-21	165-173	vascular	abstract[6]|substance[7]|substance[8]|event[9]	new[6]|new[7]|new[8]|new[9]	coref	4-14[28_9]
2-22	174-184	remodeling	abstract[6]|substance[7]|substance[8]|event[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-23	185-192	induced	_	_	_	_
2-24	193-195	by	_	_	_	_
2-25	196-208	hypertension	abstract	new	coref	10-27
2-26	209-211	in	_	_	_	_
2-27	212-213	a	abstract[13]	new[13]	_	_
2-28	214-217	SHR	object|abstract[13]	new|new[13]	coref	4-22
2-29	218-221	rat	animal|abstract[13]	new|new[13]	_	_
2-30	222-227	model	abstract[13]	new[13]	_	_
2-31	228-229	.	_	_	_	_

#Text=Our study showed highly beneficial effects including attenuation of arterial pressure and improvement of vascular reactivity .
3-1	230-233	Our	person|abstract[15]	giv|new[15]	ana|ana	12-3|12-3
3-2	234-239	study	abstract[15]	new[15]	_	_
3-3	240-246	showed	_	_	_	_
3-4	247-253	highly	abstract[16]	giv[16]	_	_
3-5	254-264	beneficial	abstract[16]	giv[16]	_	_
3-6	265-272	effects	abstract[16]	giv[16]	_	_
3-7	273-282	including	abstract[16]	giv[16]	_	_
3-8	283-294	attenuation	abstract[16]|abstract[17]	giv[16]|new[17]	_	_
3-9	295-297	of	abstract[16]|abstract[17]	giv[16]|new[17]	_	_
3-10	298-306	arterial	abstract[16]|abstract[17]|substance|abstract[19]	giv[16]|new[17]|new|new[19]	coref|coref	4-8|4-8
3-11	307-315	pressure	abstract[16]|abstract[17]|abstract[19]	giv[16]|new[17]|new[19]	_	_
3-12	316-319	and	abstract[16]|abstract[17]	giv[16]|new[17]	_	_
3-13	320-331	improvement	abstract[16]|abstract[17]|abstract[20]	giv[16]|new[17]|new[20]	_	_
3-14	332-334	of	abstract[16]|abstract[17]|abstract[20]	giv[16]|new[17]|new[20]	_	_
3-15	335-343	vascular	abstract[16]|abstract[17]|abstract[20]|abstract[21]	giv[16]|new[17]|new[20]|new[21]	_	_
3-16	344-354	reactivity	abstract[16]|abstract[17]|abstract[20]|abstract[21]	giv[16]|new[17]|new[20]|new[21]	_	_
3-17	355-356	.	_	_	_	_

#Text=These benefits were associated with reduction in arterial thickness and stiffness caused by the structural remodeling of the aortic wall in SHR .
4-1	357-362	These	abstract[22]	new[22]	_	_
4-2	363-371	benefits	abstract[22]	new[22]	_	_
4-3	372-376	were	_	_	_	_
4-4	377-387	associated	_	_	_	_
4-5	388-392	with	_	_	_	_
4-6	393-402	reduction	abstract[23]	new[23]	coref	10-6[65_23]
4-7	403-405	in	abstract[23]	new[23]	_	_
4-8	406-414	arterial	abstract[23]|quantity|abstract[25]|abstract[26]	new[23]|giv|new[25]|new[26]	ana|coref|ana|coref|ana|coref	5-1[0_26]|8-9|5-1[0_26]|8-9|5-1[0_26]|8-9
4-9	415-424	thickness	abstract[23]|abstract[25]|abstract[26]	new[23]|new[25]|new[26]	_	_
4-10	425-428	and	abstract[23]|abstract[26]	new[23]|new[26]	_	_
4-11	429-438	stiffness	abstract[23]|abstract[26]|abstract	new[23]|new[26]|new	coref	10-3[64_0]
4-12	439-445	caused	_	_	_	_
4-13	446-448	by	_	_	_	_
4-14	449-452	the	event[28]	giv[28]	coref	10-23[71_28]
4-15	453-463	structural	event[28]	giv[28]	_	_
4-16	464-474	remodeling	event[28]	giv[28]	_	_
4-17	475-477	of	event[28]	giv[28]	_	_
4-18	478-481	the	event[28]|object[30]	giv[28]|new[30]	coref	13-9[0_30]
4-19	482-488	aortic	event[28]|place|object[30]	giv[28]|new|new[30]	coref	20-3
4-20	489-493	wall	event[28]|object[30]	giv[28]|new[30]	_	_
4-21	494-496	in	event[28]|object[30]	giv[28]|new[30]	_	_
4-22	497-500	SHR	event[28]|object[30]|abstract	giv[28]|new[30]|giv	coref	12-19
4-23	501-502	.	_	_	_	_

#Text=They were mainly attributable to Si enrichment .
5-1	503-507	They	abstract	giv	_	_
5-2	508-512	were	_	_	_	_
5-3	513-519	mainly	_	_	_	_
5-4	520-532	attributable	_	_	_	_
5-5	533-535	to	_	_	_	_
5-6	536-538	Si	person|abstract[34]	new|new[34]	coref|coref	27-29|27-29
5-7	539-549	enrichment	abstract[34]	new[34]	_	_
5-8	550-551	.	_	_	_	_

#Text=Beneficial and safe effects of SpSi supplementation were previously reported in high fat diet-induced models of atherosclerosis in hamsters and metabolic syndrome in rats .
6-1	552-562	Beneficial	abstract[35]	new[35]	coref	8-6[55_35]
6-2	563-566	and	abstract[35]	new[35]	_	_
6-3	567-571	safe	abstract[35]	new[35]	_	_
6-4	572-579	effects	abstract[35]	new[35]	_	_
6-5	580-582	of	abstract[35]	new[35]	_	_
6-6	583-587	SpSi	abstract[35]|substance|substance[37]	new[35]|new|giv[37]	coref|coref|coref|coref	7-14[51_0]|7-17[53_37]|7-14[51_0]|7-17[53_37]
6-7	588-603	supplementation	abstract[35]|substance[37]	new[35]|giv[37]	_	_
6-8	604-608	were	_	_	_	_
6-9	609-619	previously	_	_	_	_
6-10	620-628	reported	_	_	_	_
6-11	629-631	in	_	_	_	_
6-12	632-636	high	substance[38]	new[38]	_	_
6-13	637-640	fat	substance[38]	new[38]	_	_
6-14	641-653	diet-induced	abstract[39]	new[39]	_	_
6-15	654-660	models	abstract[39]	new[39]	_	_
6-16	661-663	of	abstract[39]	new[39]	_	_
6-17	664-679	atherosclerosis	abstract[39]|abstract[40]	new[39]|new[40]	_	_
6-18	680-682	in	abstract[39]|abstract[40]	new[39]|new[40]	_	_
6-19	683-691	hamsters	abstract[39]|abstract[40]|animal	new[39]|new[40]|new	_	_
6-20	692-695	and	abstract[39]|abstract[40]	new[39]|new[40]	_	_
6-21	696-705	metabolic	abstract[39]|abstract[40]|person|abstract[43]	new[39]|new[40]|new|new[43]	_	_
6-22	706-714	syndrome	abstract[39]|abstract[40]|abstract[43]	new[39]|new[40]|new[43]	_	_
6-23	715-717	in	abstract[39]|abstract[40]|abstract[43]	new[39]|new[40]|new[43]	_	_
6-24	718-722	rats	abstract[39]|abstract[40]|abstract[43]|animal	new[39]|new[40]|new[43]|new	_	_
6-25	723-724	.	_	_	_	_

#Text=Improvement of glucose tolerance , insulin resistance , or dyslipidemia were evidenced with both SpSi and Sp supplementation .
7-1	725-736	Improvement	abstract[45]	new[45]	_	_
7-2	737-739	of	abstract[45]	new[45]	_	_
7-3	740-747	glucose	abstract[45]|substance|abstract[47]	new[45]|new|new[47]	_	_
7-4	748-757	tolerance	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-5	758-759	,	abstract[45]	new[45]	_	_
7-6	760-767	insulin	abstract[45]|event|abstract[49]	new[45]|new|new[49]	_	_
7-7	768-778	resistance	abstract[45]|abstract[49]	new[45]|new[49]	_	_
7-8	779-780	,	abstract[45]	new[45]	_	_
7-9	781-783	or	abstract[45]	new[45]	_	_
7-10	784-796	dyslipidemia	abstract[45]|abstract	new[45]|new	_	_
7-11	797-801	were	_	_	_	_
7-12	802-811	evidenced	_	_	_	_
7-13	812-816	with	_	_	_	_
7-14	817-821	both	substance[51]	giv[51]	coref	8-4[0_51]
7-15	822-826	SpSi	substance[51]	giv[51]	_	_
7-16	827-830	and	_	_	_	_
7-17	831-833	Sp	abstract|substance[53]	new|giv[53]	coref|coref|coref|coref	19-5[0_53]|27-11|19-5[0_53]|27-11
7-18	834-849	supplementation	substance[53]	giv[53]	_	_
7-19	850-851	.	_	_	_	_

#Text=However , only SpSi had beneficial effects on arterial function .
8-1	852-859	However	_	_	_	_
8-2	860-861	,	_	_	_	_
8-3	862-866	only	_	_	_	_
8-4	867-871	SpSi	substance	giv	coref	9-7
8-5	872-875	had	_	_	_	_
8-6	876-886	beneficial	abstract[55]	giv[55]	_	_
8-7	887-894	effects	abstract[55]	giv[55]	_	_
8-8	895-897	on	abstract[55]	giv[55]	_	_
8-9	898-906	arterial	abstract[55]|substance|abstract[57]	giv[55]|giv|new[57]	coref|coref|coref|coref	13-8|18-28[137_57]|13-8|18-28[137_57]
8-10	907-915	function	abstract[55]|abstract[57]	giv[55]|new[57]	_	_
8-11	916-917	.	_	_	_	_

#Text=No toxicity or side effects of SpSi supplement were otherwise observed .
9-1	918-920	No	abstract[58]	new[58]	_	_
9-2	921-929	toxicity	abstract[58]	new[58]	_	_
9-3	930-932	or	_	_	_	_
9-4	933-937	side	abstract|abstract[60]	new|new[60]	_	_
9-5	938-945	effects	abstract[60]	new[60]	_	_
9-6	946-948	of	abstract[60]	new[60]	_	_
9-7	949-953	SpSi	abstract[60]|substance|substance[62]	new[60]|giv|new[62]	coref|coref	12-8[83_0]|12-8[83_0]
9-8	954-964	supplement	abstract[60]|substance[62]	new[60]|new[62]	_	_
9-9	965-969	were	_	_	_	_
9-10	970-979	otherwise	_	_	_	_
9-11	980-988	observed	_	_	_	_
9-12	989-990	.	_	_	_	_

#Text=Increase of arterial stiffness , reduction of arterial compliance , and distensibility marked by fragmentation of elastin are the main consequences of arterial remodeling occurring in hypertension , obesity and aging .
10-1	991-999	Increase	abstract[63]	new[63]	coref	10-19[70_63]
10-2	1000-1002	of	abstract[63]	new[63]	_	_
10-3	1003-1011	arterial	abstract[63]|abstract[64]	new[63]|giv[64]	_	_
10-4	1012-1021	stiffness	abstract[63]|abstract[64]	new[63]|giv[64]	_	_
10-5	1022-1023	,	abstract[63]	new[63]	_	_
10-6	1024-1033	reduction	abstract[63]|abstract[65]	new[63]|giv[65]	coref	11-12[78_65]
10-7	1034-1036	of	abstract[63]|abstract[65]	new[63]|giv[65]	_	_
10-8	1037-1045	arterial	abstract[63]|abstract[65]|abstract[66]	new[63]|giv[65]|new[66]	coref	14-12[0_66]
10-9	1046-1056	compliance	abstract[63]|abstract[65]|abstract[66]	new[63]|giv[65]|new[66]	_	_
10-10	1057-1058	,	abstract[63]	new[63]	_	_
10-11	1059-1062	and	abstract[63]	new[63]	_	_
10-12	1063-1077	distensibility	abstract[63]|abstract	new[63]|new	coref	14-14
10-13	1078-1084	marked	_	_	_	_
10-14	1085-1087	by	_	_	_	_
10-15	1088-1101	fragmentation	abstract[68]	new[68]	coref	13-15[0_68]
10-16	1102-1104	of	abstract[68]	new[68]	_	_
10-17	1105-1112	elastin	abstract[68]|substance	new[68]|new	coref	11-14
10-18	1113-1116	are	_	_	_	_
10-19	1117-1120	the	abstract[70]	giv[70]	_	_
10-20	1121-1125	main	abstract[70]	giv[70]	_	_
10-21	1126-1138	consequences	abstract[70]	giv[70]	_	_
10-22	1139-1141	of	abstract[70]	giv[70]	_	_
10-23	1142-1150	arterial	abstract[70]|event[71]	giv[70]|giv[71]	coref	11-1[75_71]
10-24	1151-1161	remodeling	abstract[70]|event[71]	giv[70]|giv[71]	_	_
10-25	1162-1171	occurring	_	_	_	_
10-26	1172-1174	in	_	_	_	_
10-27	1175-1187	hypertension	abstract	giv	coref	11-4
10-28	1188-1189	,	_	_	_	_
10-29	1190-1197	obesity	abstract	new	_	_
10-30	1198-1201	and	_	_	_	_
10-31	1202-1207	aging	abstract	new	_	_
10-32	1208-1209	.	_	_	_	_

#Text=Vascular remodeling in hypertension is characterized by altered ultrastructure due to reduction in elastin and increase in fibrous tissue .
11-1	1210-1218	Vascular	event[75]	giv[75]	coref	22-5[163_75]
11-2	1219-1229	remodeling	event[75]	giv[75]	_	_
11-3	1230-1232	in	event[75]	giv[75]	_	_
11-4	1233-1245	hypertension	event[75]|abstract	giv[75]|giv	coref	14-17
11-5	1246-1248	is	_	_	_	_
11-6	1249-1262	characterized	_	_	_	_
11-7	1263-1265	by	_	_	_	_
11-8	1266-1273	altered	abstract[77]	new[77]	_	_
11-9	1274-1288	ultrastructure	abstract[77]	new[77]	_	_
11-10	1289-1292	due	_	_	_	_
11-11	1293-1295	to	_	_	_	_
11-12	1296-1305	reduction	abstract[78]	giv[78]	_	_
11-13	1306-1308	in	abstract[78]	giv[78]	_	_
11-14	1309-1316	elastin	abstract[78]|substance	giv[78]|giv	coref	15-18
11-15	1317-1320	and	_	_	_	_
11-16	1321-1329	increase	_	_	_	_
11-17	1330-1332	in	_	_	_	_
11-18	1333-1340	fibrous	object[80]	new[80]	_	_
11-19	1341-1347	tissue	object[80]	new[80]	_	_
11-20	1348-1349	.	_	_	_	_

#Text=Here , we assessed the effect of SpSi on the ultrastructural , mechanical and functional changes characterized in SHR thoracic aorta .
12-1	1350-1354	Here	_	_	_	_
12-2	1355-1356	,	_	_	_	_
12-3	1357-1359	we	person	giv	ana	15-7
12-4	1360-1368	assessed	_	_	_	_
12-5	1369-1372	the	abstract[82]	new[82]	_	_
12-6	1373-1379	effect	abstract[82]	new[82]	_	_
12-7	1380-1382	of	abstract[82]	new[82]	_	_
12-8	1383-1387	SpSi	abstract[82]|substance[83]	new[82]|giv[83]	coref	19-7[0_83]
12-9	1388-1390	on	abstract[82]|substance[83]	new[82]|giv[83]	_	_
12-10	1391-1394	the	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	coref	14-1[98_84]
12-11	1395-1410	ultrastructural	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-12	1411-1412	,	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-13	1413-1423	mechanical	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-14	1424-1427	and	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-15	1428-1438	functional	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-16	1439-1446	changes	abstract[82]|substance[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
12-17	1447-1460	characterized	_	_	_	_
12-18	1461-1463	in	_	_	_	_
12-19	1464-1467	SHR	abstract|object[86]	giv|new[86]	coref|coref|coref|coref	15-4|15-4[105_86]|15-4|15-4[105_86]
12-20	1468-1476	thoracic	object[86]	new[86]	_	_
12-21	1477-1482	aorta	object[86]	new[86]	_	_
12-22	1483-1484	.	_	_	_	_

#Text=These modifications consisted of ( i ) arterial wall hypertrophy , ( ii ) fragmentation , linearization , and refolding of elastic fibers , and ( iii ) impaired contractile and vasorelaxant responses .
13-1	1485-1490	These	abstract[87]	new[87]	_	_
13-2	1491-1504	modifications	abstract[87]	new[87]	_	_
13-3	1505-1514	consisted	_	_	_	_
13-4	1515-1517	of	_	_	_	_
13-5	1518-1519	(	_	_	_	_
13-6	1520-1521	i	_	_	_	_
13-7	1522-1523	)	_	_	_	_
13-8	1524-1532	arterial	substance|abstract[90]	giv|new[90]	appos|coref|appos|coref	13-13[0_90]|26-1|13-13[0_90]|26-1
13-9	1533-1537	wall	object|abstract[90]	giv|new[90]	coref	29-11[213_0]
13-10	1538-1549	hypertrophy	abstract[90]	new[90]	_	_
13-11	1550-1551	,	_	_	_	_
13-12	1552-1553	(	_	_	_	_
13-13	1554-1556	ii	abstract	giv	coref	20-3[146_0]
13-14	1557-1558	)	_	_	_	_
13-15	1559-1572	fragmentation	abstract	giv	coref	15-19
13-16	1573-1574	,	_	_	_	_
13-17	1575-1588	linearization	abstract	new	_	_
13-18	1589-1590	,	_	_	_	_
13-19	1591-1594	and	_	_	_	_
13-20	1595-1604	refolding	event[94]	new[94]	_	_
13-21	1605-1607	of	event[94]	new[94]	_	_
13-22	1608-1615	elastic	event[94]|object[95]	new[94]|new[95]	appos	13-27[0_95]
13-23	1616-1622	fibers	event[94]|object[95]	new[94]|new[95]	_	_
13-24	1623-1624	,	_	_	_	_
13-25	1625-1628	and	_	_	_	_
13-26	1629-1630	(	_	_	_	_
13-27	1631-1634	iii	object	giv	coref	32-6[234_0]
13-28	1635-1636	)	_	_	_	_
13-29	1637-1645	impaired	_	_	_	_
13-30	1646-1657	contractile	abstract[97]	new[97]	coref	17-1[123_97]
13-31	1658-1661	and	abstract[97]	new[97]	_	_
13-32	1662-1674	vasorelaxant	abstract[97]	new[97]	_	_
13-33	1675-1684	responses	abstract[97]	new[97]	_	_
13-34	1685-1686	.	_	_	_	_

#Text=These changes typified the degenerative processes leading to the reduction of compliance and distensibility described in hypertension and associated with aging .
14-1	1687-1692	These	abstract[98]	giv[98]	_	_
14-2	1693-1700	changes	abstract[98]	giv[98]	_	_
14-3	1701-1709	typified	_	_	_	_
14-4	1710-1713	the	abstract[99]	new[99]	_	_
14-5	1714-1726	degenerative	abstract[99]	new[99]	_	_
14-6	1727-1736	processes	abstract[99]	new[99]	_	_
14-7	1737-1744	leading	_	_	_	_
14-8	1745-1747	to	_	_	_	_
14-9	1748-1751	the	abstract[100]	new[100]	coref	33-13[0_100]
14-10	1752-1761	reduction	abstract[100]	new[100]	_	_
14-11	1762-1764	of	abstract[100]	new[100]	_	_
14-12	1765-1775	compliance	abstract[100]|abstract	new[100]|giv	_	_
14-13	1776-1779	and	abstract[100]	new[100]	_	_
14-14	1780-1794	distensibility	abstract[100]|abstract	new[100]|giv	_	_
14-15	1795-1804	described	_	_	_	_
14-16	1805-1807	in	_	_	_	_
14-17	1808-1820	hypertension	abstract	giv	coref	26-29
14-18	1821-1824	and	_	_	_	_
14-19	1825-1835	associated	_	_	_	_
14-20	1836-1840	with	_	_	_	_
14-21	1841-1846	aging	_	_	_	_
14-22	1847-1848	.	_	_	_	_

#Text=Indeed , in SHR aorta , our results showed enlarged internal diameter and media thickening , increased elastin fragmentation ratio , and lower elastin and collagen levels than in normotensive animals .
15-1	1849-1855	Indeed	_	_	_	_
15-2	1856-1857	,	_	_	_	_
15-3	1858-1860	in	_	_	_	_
15-4	1861-1864	SHR	abstract|object[105]	giv|giv[105]	coref|coref|coref|coref	18-18[0_105]|18-20|18-18[0_105]|18-20
15-5	1865-1870	aorta	object[105]	giv[105]	_	_
15-6	1871-1872	,	_	_	_	_
15-7	1873-1876	our	person|abstract[107]	giv|new[107]	ana|coref|ana|coref	23-3|33-3[243_107]|23-3|33-3[243_107]
15-8	1877-1884	results	abstract[107]	new[107]	_	_
15-9	1885-1891	showed	_	_	_	_
15-10	1892-1900	enlarged	quantity[108]	new[108]	_	_
15-11	1901-1909	internal	quantity[108]	new[108]	_	_
15-12	1910-1918	diameter	quantity[108]	new[108]	_	_
15-13	1919-1922	and	_	_	_	_
15-14	1923-1928	media	abstract|abstract[110]	new|new[110]	coref|coref|coref|coref	21-31|32-4[233_110]|21-31|32-4[233_110]
15-15	1929-1939	thickening	abstract[110]	new[110]	_	_
15-16	1940-1941	,	_	_	_	_
15-17	1942-1951	increased	abstract[113]	new[113]	_	_
15-18	1952-1959	elastin	abstract|abstract[113]	giv|new[113]	coref	15-23[114_0]
15-19	1960-1973	fragmentation	abstract|abstract[113]	giv|new[113]	_	_
15-20	1974-1979	ratio	abstract[113]	new[113]	_	_
15-21	1980-1981	,	_	_	_	_
15-22	1982-1985	and	_	_	_	_
15-23	1986-1991	lower	substance[114]	giv[114]	coref	21-4[0_114]
15-24	1992-1999	elastin	substance[114]	giv[114]	_	_
15-25	2000-2003	and	_	_	_	_
15-26	2004-2012	collagen	organization|abstract[116]	new|new[116]	coref|coref	29-19|29-19
15-27	2013-2019	levels	abstract[116]	new[116]	_	_
15-28	2020-2024	than	abstract[116]	new[116]	_	_
15-29	2025-2027	in	abstract[116]	new[116]	_	_
15-30	2028-2040	normotensive	abstract[116]|animal[117]	new[116]|new[117]	coref	25-6[183_117]
15-31	2041-2048	animals	abstract[116]|animal[117]	new[116]|new[117]	_	_
15-32	2049-2050	.	_	_	_	_

#Text=Consequently , contractility was impaired as evidenced by the decreased response and sensitivities to KCl-induced depolarization and PE .
16-1	2051-2063	Consequently	_	_	_	_
16-2	2064-2065	,	_	_	_	_
16-3	2066-2079	contractility	abstract	new	_	_
16-4	2080-2083	was	_	_	_	_
16-5	2084-2092	impaired	_	_	_	_
16-6	2093-2095	as	_	_	_	_
16-7	2096-2105	evidenced	_	_	_	_
16-8	2106-2108	by	_	_	_	_
16-9	2109-2112	the	abstract[119]	new[119]	_	_
16-10	2113-2122	decreased	abstract[119]	new[119]	_	_
16-11	2123-2131	response	abstract[119]	new[119]	_	_
16-12	2132-2135	and	_	_	_	_
16-13	2136-2149	sensitivities	abstract[120]	new[120]	_	_
16-14	2150-2152	to	abstract[120]	new[120]	_	_
16-15	2153-2164	KCl-induced	abstract[120]|abstract[121]	new[120]|new[121]	_	_
16-16	2165-2179	depolarization	abstract[120]|abstract[121]	new[120]|new[121]	_	_
16-17	2180-2183	and	abstract[120]	new[120]	_	_
16-18	2184-2186	PE	abstract[120]|abstract	new[120]|new	_	_
16-19	2187-2188	.	_	_	_	_

#Text=The vasorelaxant responses to both Ach and SNP were also reduced .
17-1	2189-2192	The	abstract[123]	giv[123]	coref	24-1[175_123]
17-2	2193-2205	vasorelaxant	abstract[123]	giv[123]	_	_
17-3	2206-2215	responses	abstract[123]	giv[123]	_	_
17-4	2216-2218	to	abstract[123]	giv[123]	_	_
17-5	2219-2223	both	abstract[123]|abstract[124]	giv[123]|new[124]	_	_
17-6	2224-2227	Ach	abstract[123]|abstract[124]	giv[123]|new[124]	_	_
17-7	2228-2231	and	abstract[123]	giv[123]	_	_
17-8	2232-2235	SNP	abstract[123]|abstract	giv[123]|new	_	_
17-9	2236-2240	were	_	_	_	_
17-10	2241-2245	also	_	_	_	_
17-11	2246-2253	reduced	_	_	_	_
17-12	2254-2255	.	_	_	_	_

#Text=The enhanced effect of L-NAME on PE-induced contraction suggested that the decrease in the vasodilator capacity of aorta in SHR is due to both the alteration of vascular smooth muscle function and NO bioavailability .
18-1	2256-2259	The	abstract[126]	new[126]	coref	27-14[203_126]
18-2	2260-2268	enhanced	abstract[126]	new[126]	_	_
18-3	2269-2275	effect	abstract[126]	new[126]	_	_
18-4	2276-2278	of	abstract[126]	new[126]	_	_
18-5	2279-2285	L-NAME	abstract[126]|substance[127]	new[126]|new[127]	_	_
18-6	2286-2288	on	abstract[126]|substance[127]	new[126]|new[127]	_	_
18-7	2289-2299	PE-induced	abstract[126]|substance[127]|abstract|event[129]	new[126]|new[127]|new|new[129]	_	_
18-8	2300-2311	contraction	abstract[126]|substance[127]|event[129]	new[126]|new[127]|new[129]	_	_
18-9	2312-2321	suggested	_	_	_	_
18-10	2322-2326	that	_	_	_	_
18-11	2327-2330	the	event[130]	new[130]	coref	21-13[154_130]
18-12	2331-2339	decrease	event[130]	new[130]	_	_
18-13	2340-2342	in	event[130]	new[130]	_	_
18-14	2343-2346	the	event[130]|abstract[132]	new[130]|new[132]	_	_
18-15	2347-2358	vasodilator	event[130]|object|abstract[132]	new[130]|new|new[132]	_	_
18-16	2359-2367	capacity	event[130]|abstract[132]	new[130]|new[132]	_	_
18-17	2368-2370	of	event[130]|abstract[132]	new[130]|new[132]	_	_
18-18	2371-2376	aorta	event[130]|abstract[132]|object	new[130]|new[132]|giv	coref	19-19[144_0]
18-19	2377-2379	in	event[130]|abstract[132]	new[130]|new[132]	_	_
18-20	2380-2383	SHR	event[130]|abstract[132]|object	new[130]|new[132]|giv	coref	19-19
18-21	2384-2386	is	_	_	_	_
18-22	2387-2390	due	_	_	_	_
18-23	2391-2393	to	_	_	_	_
18-24	2394-2398	both	abstract[135]	new[135]	_	_
18-25	2399-2402	the	abstract[135]	new[135]	_	_
18-26	2403-2413	alteration	abstract[135]	new[135]	_	_
18-27	2414-2416	of	abstract[135]	new[135]	_	_
18-28	2417-2425	vascular	abstract[135]|abstract[137]	new[135]|giv[137]	coref	23-8[172_137]
18-29	2426-2432	smooth	abstract[135]|abstract[137]	new[135]|giv[137]	_	_
18-30	2433-2439	muscle	abstract[135]|object|abstract[137]	new[135]|new|giv[137]	_	_
18-31	2440-2448	function	abstract[135]|abstract[137]	new[135]|giv[137]	_	_
18-32	2449-2452	and	abstract[135]	new[135]	_	_
18-33	2453-2455	NO	abstract[135]|substance[138]	new[135]|new[138]	coref	24-20[180_138]
18-34	2456-2471	bioavailability	abstract[135]|substance[138]	new[135]|new[138]	_	_
18-35	2472-2473	.	_	_	_	_

#Text=After three months of supplementation , SpSi substantially corrected and even normalized most of the defects identified in SHR aorta .
19-1	2474-2479	After	_	_	_	_
19-2	2480-2485	three	time[139]	new[139]	_	_
19-3	2486-2492	months	time[139]	new[139]	_	_
19-4	2493-2495	of	time[139]	new[139]	_	_
19-5	2496-2511	supplementation	time[139]|substance	new[139]|giv	coref	23-11[174_0]
19-6	2512-2513	,	_	_	_	_
19-7	2514-2518	SpSi	abstract	giv	coref	23-11
19-8	2519-2532	substantially	_	_	_	_
19-9	2533-2542	corrected	_	_	_	_
19-10	2543-2546	and	_	_	_	_
19-11	2547-2551	even	_	_	_	_
19-12	2552-2562	normalized	_	_	_	_
19-13	2563-2567	most	abstract[142]	new[142]	_	_
19-14	2568-2570	of	abstract[142]	new[142]	_	_
19-15	2571-2574	the	abstract[142]	new[142]	_	_
19-16	2575-2582	defects	abstract[142]	new[142]	_	_
19-17	2583-2593	identified	_	_	_	_
19-18	2594-2596	in	_	_	_	_
19-19	2597-2600	SHR	abstract|object[144]	giv|giv[144]	coref|coref	25-6|25-6
19-20	2601-2606	aorta	object[144]	giv[144]	_	_
19-21	2607-2608	.	_	_	_	_

#Text=First , aortic hypertrophy was reduced as shown by morphologic analysis .
20-1	2609-2614	First	_	_	_	_
20-2	2615-2616	,	_	_	_	_
20-3	2617-2623	aortic	abstract|abstract[146]	giv|giv[146]	coref|coref	29-12|29-12
20-4	2624-2635	hypertrophy	abstract[146]	giv[146]	_	_
20-5	2636-2639	was	_	_	_	_
20-6	2640-2647	reduced	_	_	_	_
20-7	2648-2650	as	_	_	_	_
20-8	2651-2656	shown	_	_	_	_
20-9	2657-2659	by	_	_	_	_
20-10	2660-2671	morphologic	abstract[147]	new[147]	_	_
20-11	2672-2680	analysis	abstract[147]	new[147]	_	_
20-12	2681-2682	.	_	_	_	_

#Text=Higher level of elastin fiber density and mRNA level were associated to a decrease in MMP-9 expression , suggesting that both enhanced elastin biosynthesis and reduced extracellular matrix contributed to media thinning .
21-1	2683-2689	Higher	abstract[148]	new[148]	_	_
21-2	2690-2695	level	abstract[148]	new[148]	_	_
21-3	2696-2698	of	abstract[148]	new[148]	_	_
21-4	2699-2706	elastin	abstract[148]|substance|abstract[151]	new[148]|giv|new[151]	coref|coref	21-23|21-23
21-5	2707-2712	fiber	abstract[148]|substance|abstract[151]	new[148]|new|new[151]	coref	37-15
21-6	2713-2720	density	abstract[148]|abstract[151]	new[148]|new[151]	_	_
21-7	2721-2724	and	abstract[148]	new[148]	_	_
21-8	2725-2729	mRNA	abstract[148]|place|abstract[153]	new[148]|new|new[153]	coref|coref	39-5[282_153]|39-5[282_153]
21-9	2730-2735	level	abstract[148]|abstract[153]	new[148]|new[153]	_	_
21-10	2736-2740	were	_	_	_	_
21-11	2741-2751	associated	_	_	_	_
21-12	2752-2754	to	_	_	_	_
21-13	2755-2756	a	event[154]	giv[154]	_	_
21-14	2757-2765	decrease	event[154]	giv[154]	_	_
21-15	2766-2768	in	event[154]	giv[154]	_	_
21-16	2769-2774	MMP-9	event[154]|person|abstract[156]	giv[154]|new|new[156]	_	_
21-17	2775-2785	expression	event[154]|abstract[156]	giv[154]|new[156]	_	_
21-18	2786-2787	,	_	_	_	_
21-19	2788-2798	suggesting	_	_	_	_
21-20	2799-2803	that	_	_	_	_
21-21	2804-2808	both	abstract[158]	new[158]	_	_
21-22	2809-2817	enhanced	abstract[158]	new[158]	_	_
21-23	2818-2825	elastin	substance|abstract[158]	giv|new[158]	coref	29-17
21-24	2826-2838	biosynthesis	abstract[158]	new[158]	_	_
21-25	2839-2842	and	_	_	_	_
21-26	2843-2850	reduced	abstract[159]	new[159]	coref	22-13[166_159]
21-27	2851-2864	extracellular	abstract[159]	new[159]	_	_
21-28	2865-2871	matrix	abstract[159]	new[159]	_	_
21-29	2872-2883	contributed	_	_	_	_
21-30	2884-2886	to	_	_	_	_
21-31	2887-2892	media	abstract|abstract[161]	giv|new[161]	ana|ana	22-1[0_161]|22-1[0_161]
21-32	2893-2901	thinning	abstract[161]	new[161]	_	_
21-33	2902-2903	.	_	_	_	_

#Text=It is known that hypertensive vascular remodeling involves reorganization and impairment of the extracellular matrix and that MMPs play an important role in this remodeling .
22-1	2904-2906	It	abstract	giv	_	_
22-2	2907-2909	is	_	_	_	_
22-3	2910-2915	known	_	_	_	_
22-4	2916-2920	that	_	_	_	_
22-5	2921-2933	hypertensive	event[163]	giv[163]	coref	22-24[169_163]
22-6	2934-2942	vascular	event[163]	giv[163]	_	_
22-7	2943-2953	remodeling	event[163]	giv[163]	_	_
22-8	2954-2962	involves	_	_	_	_
22-9	2963-2977	reorganization	event	new	_	_
22-10	2978-2981	and	_	_	_	_
22-11	2982-2992	impairment	event[165]	new[165]	_	_
22-12	2993-2995	of	event[165]	new[165]	_	_
22-13	2996-2999	the	event[165]|abstract[166]	new[165]|giv[166]	_	_
22-14	3000-3013	extracellular	event[165]|abstract[166]	new[165]|giv[166]	_	_
22-15	3014-3020	matrix	event[165]|abstract[166]	new[165]|giv[166]	_	_
22-16	3021-3024	and	_	_	_	_
22-17	3025-3029	that	_	_	_	_
22-18	3030-3034	MMPs	abstract	new	_	_
22-19	3035-3039	play	_	_	_	_
22-20	3040-3042	an	abstract[168]	giv[168]	_	_
22-21	3043-3052	important	abstract[168]	giv[168]	_	_
22-22	3053-3057	role	abstract[168]	giv[168]	_	_
22-23	3058-3060	in	abstract[168]	giv[168]	_	_
22-24	3061-3065	this	abstract[168]|event[169]	giv[168]|giv[169]	_	_
22-25	3066-3076	remodeling	abstract[168]|event[169]	giv[168]|giv[169]	_	_
22-26	3077-3078	.	_	_	_	_

#Text=Second , we observed an improvement of vascular function after SpSi supplementation .
23-1	3079-3085	Second	_	_	_	_
23-2	3086-3087	,	_	_	_	_
23-3	3088-3090	we	person	giv	ana	25-3
23-4	3091-3099	observed	_	_	_	_
23-5	3100-3102	an	abstract[171]	new[171]	_	_
23-6	3103-3114	improvement	abstract[171]	new[171]	_	_
23-7	3115-3117	of	abstract[171]	new[171]	_	_
23-8	3118-3126	vascular	abstract[171]|abstract[172]	new[171]|giv[172]	coref	35-15[260_172]
23-9	3127-3135	function	abstract[171]|abstract[172]	new[171]|giv[172]	_	_
23-10	3136-3141	after	_	_	_	_
23-11	3142-3146	SpSi	substance|substance[174]	giv|giv[174]	coref|coref|coref|coref	25-10|26-36[0_174]|25-10|26-36[0_174]
23-12	3147-3162	supplementation	substance[174]	giv[174]	_	_
23-13	3163-3164	.	_	_	_	_

#Text=Contractile and vasorelaxant responses were increased in association with an increased sensitivity to the agonists and antagonists tested and a better NO bioavailability .
24-1	3165-3176	Contractile	abstract[175]	giv[175]	_	_
24-2	3177-3180	and	abstract[175]	giv[175]	_	_
24-3	3181-3193	vasorelaxant	abstract[175]	giv[175]	_	_
24-4	3194-3203	responses	abstract[175]	giv[175]	_	_
24-5	3204-3208	were	_	_	_	_
24-6	3209-3218	increased	_	_	_	_
24-7	3219-3221	in	_	_	_	_
24-8	3222-3233	association	abstract	new	_	_
24-9	3234-3238	with	_	_	_	_
24-10	3239-3241	an	abstract[177]	new[177]	_	_
24-11	3242-3251	increased	abstract[177]	new[177]	_	_
24-12	3252-3263	sensitivity	abstract[177]	new[177]	_	_
24-13	3264-3266	to	abstract[177]	new[177]	_	_
24-14	3267-3270	the	abstract[177]|abstract[178]	new[177]|new[178]	_	_
24-15	3271-3279	agonists	abstract[177]|abstract[178]	new[177]|new[178]	_	_
24-16	3280-3283	and	abstract[177]	new[177]	_	_
24-17	3284-3295	antagonists	abstract[177]|person	new[177]|new	_	_
24-18	3296-3302	tested	_	_	_	_
24-19	3303-3306	and	_	_	_	_
24-20	3307-3308	a	substance[180]	giv[180]	_	_
24-21	3309-3315	better	substance[180]	giv[180]	_	_
24-22	3316-3318	NO	substance[180]	giv[180]	_	_
24-23	3319-3334	bioavailability	substance[180]	giv[180]	_	_
24-24	3335-3336	.	_	_	_	_

#Text=Finally , we found that SHR animals supplemented with SpSi had lower arterial pressure than control SHR .
25-1	3337-3344	Finally	_	_	_	_
25-2	3345-3346	,	_	_	_	_
25-3	3347-3349	we	person	giv	ana	26-25
25-4	3350-3355	found	_	_	_	_
25-5	3356-3360	that	_	_	_	_
25-6	3361-3364	SHR	object|animal[183]	giv|giv[183]	coref|coref	25-16[186_0]|25-16[186_0]
25-7	3365-3372	animals	animal[183]	giv[183]	_	_
25-8	3373-3385	supplemented	_	_	_	_
25-9	3386-3390	with	_	_	_	_
25-10	3391-3395	SpSi	substance	giv	coref	27-24
25-11	3396-3399	had	_	_	_	_
25-12	3400-3405	lower	abstract[185]	new[185]	coref	26-1[188_185]
25-13	3406-3414	arterial	abstract[185]	new[185]	_	_
25-14	3415-3423	pressure	abstract[185]	new[185]	_	_
25-15	3424-3428	than	abstract[185]	new[185]	_	_
25-16	3429-3436	control	abstract[185]|object[186]	new[185]|giv[186]	coref	27-17[0_186]
25-17	3437-3440	SHR	abstract[185]|object[186]	new[185]|giv[186]	_	_
25-18	3441-3442	.	_	_	_	_

#Text=Arterial pressure , although significantly reduced , was still higher than normal pressure which may explain the lack of benefit on cardiac parameters in our experimental conditions ( hypertension already established , 3 months of supplementation ) .
26-1	3443-3451	Arterial	substance|abstract[188]	giv|giv[188]	coref|coref	26-12[189_188]|26-12[189_188]
26-2	3452-3460	pressure	abstract[188]	giv[188]	_	_
26-3	3461-3462	,	_	_	_	_
26-4	3463-3471	although	_	_	_	_
26-5	3472-3485	significantly	_	_	_	_
26-6	3486-3493	reduced	_	_	_	_
26-7	3494-3495	,	_	_	_	_
26-8	3496-3499	was	_	_	_	_
26-9	3500-3505	still	_	_	_	_
26-10	3506-3512	higher	_	_	_	_
26-11	3513-3517	than	_	_	_	_
26-12	3518-3524	normal	abstract[189]	giv[189]	coref	33-15[247_189]
26-13	3525-3533	pressure	abstract[189]	giv[189]	_	_
26-14	3534-3539	which	_	_	_	_
26-15	3540-3543	may	_	_	_	_
26-16	3544-3551	explain	_	_	_	_
26-17	3552-3555	the	abstract[190]	new[190]	_	_
26-18	3556-3560	lack	abstract[190]	new[190]	_	_
26-19	3561-3563	of	abstract[190]	new[190]	_	_
26-20	3564-3571	benefit	abstract[190]|abstract[191]	new[190]|new[191]	coref	37-23[276_191]
26-21	3572-3574	on	abstract[190]|abstract[191]	new[190]|new[191]	_	_
26-22	3575-3582	cardiac	abstract[190]|abstract[191]|abstract[192]	new[190]|new[191]|new[192]	_	_
26-23	3583-3593	parameters	abstract[190]|abstract[191]|abstract[192]	new[190]|new[191]|new[192]	_	_
26-24	3594-3596	in	abstract[190]|abstract[191]|abstract[192]	new[190]|new[191]|new[192]	_	_
26-25	3597-3600	our	abstract[190]|abstract[191]|abstract[192]|person|abstract[194]	new[190]|new[191]|new[192]|giv|new[194]	ana|ana	27-5|27-5
26-26	3601-3613	experimental	abstract[190]|abstract[191]|abstract[192]|abstract[194]	new[190]|new[191]|new[192]|new[194]	_	_
26-27	3614-3624	conditions	abstract[190]|abstract[191]|abstract[192]|abstract[194]	new[190]|new[191]|new[192]|new[194]	_	_
26-28	3625-3626	(	_	_	_	_
26-29	3627-3639	hypertension	abstract	giv	_	_
26-30	3640-3647	already	_	_	_	_
26-31	3648-3659	established	_	_	_	_
26-32	3660-3661	,	_	_	_	_
26-33	3662-3663	3	time[196]	new[196]	_	_
26-34	3664-3670	months	time[196]	new[196]	_	_
26-35	3671-3673	of	time[196]	new[196]	_	_
26-36	3674-3689	supplementation	time[196]|substance	new[196]|giv	coref	27-9[201_0]
26-37	3690-3691	)	_	_	_	_
26-38	3692-3693	.	_	_	_	_

#Text=Another interesting result in our study is that supplementation with Sp alone had no effect in SHR suggesting that the benefits observed with SpSi are genuine effects of Si .
27-1	3694-3701	Another	abstract[198]	new[198]	coref	37-3[269_198]
27-2	3702-3713	interesting	abstract[198]	new[198]	_	_
27-3	3714-3720	result	abstract[198]	new[198]	_	_
27-4	3721-3723	in	abstract[198]	new[198]	_	_
27-5	3724-3727	our	abstract[198]|person|abstract[200]	new[198]|giv|new[200]	ana|coref|ana|coref	33-3|33-9[244_200]|33-3|33-9[244_200]
27-6	3728-3733	study	abstract[198]|abstract[200]	new[198]|new[200]	_	_
27-7	3734-3736	is	_	_	_	_
27-8	3737-3741	that	_	_	_	_
27-9	3742-3757	supplementation	substance[201]	giv[201]	coref	32-15[238_201]
27-10	3758-3762	with	substance[201]	giv[201]	_	_
27-11	3763-3765	Sp	substance[201]|substance	giv[201]|giv	_	_
27-12	3766-3771	alone	_	_	_	_
27-13	3772-3775	had	_	_	_	_
27-14	3776-3778	no	abstract[203]	giv[203]	coref	38-13[279_203]
27-15	3779-3785	effect	abstract[203]	giv[203]	_	_
27-16	3786-3788	in	abstract[203]	giv[203]	_	_
27-17	3789-3792	SHR	abstract[203]|abstract	giv[203]|giv	coref	33-24
27-18	3793-3803	suggesting	_	_	_	_
27-19	3804-3808	that	_	_	_	_
27-20	3809-3812	the	abstract[205]	new[205]	_	_
27-21	3813-3821	benefits	abstract[205]	new[205]	_	_
27-22	3822-3830	observed	_	_	_	_
27-23	3831-3835	with	_	_	_	_
27-24	3836-3840	SpSi	substance	giv	coref	37-11
27-25	3841-3844	are	_	_	_	_
27-26	3845-3852	genuine	abstract[207]	new[207]	_	_
27-27	3853-3860	effects	abstract[207]	new[207]	_	_
27-28	3861-3863	of	abstract[207]	new[207]	_	_
27-29	3864-3866	Si	abstract[207]|abstract	new[207]|giv	coref	28-5
27-30	3867-3868	.	_	_	_	_

#Text=The nutritional essentiality of Si is undeniable .
28-1	3869-3872	The	abstract[209]	new[209]	_	_
28-2	3873-3884	nutritional	abstract[209]	new[209]	_	_
28-3	3885-3897	essentiality	abstract[209]	new[209]	_	_
28-4	3898-3900	of	abstract[209]	new[209]	_	_
28-5	3901-3903	Si	abstract[209]|person	new[209]|giv	coref	30-9[222_0]
28-6	3904-3906	is	_	_	_	_
28-7	3907-3917	undeniable	_	_	_	_
28-8	3918-3919	.	_	_	_	_

#Text=This organic element appears as an important structural component of the aortic wall which contributes to elastin and collagen synthesis and stability .
29-1	3920-3924	This	substance[211]	new[211]	_	_
29-2	3925-3932	organic	substance[211]	new[211]	_	_
29-3	3933-3940	element	substance[211]	new[211]	_	_
29-4	3941-3948	appears	_	_	_	_
29-5	3949-3951	as	_	_	_	_
29-6	3952-3954	an	_	_	_	_
29-7	3955-3964	important	_	_	_	_
29-8	3965-3975	structural	_	_	_	_
29-9	3976-3985	component	_	_	_	_
29-10	3986-3988	of	_	_	_	_
29-11	3989-3992	the	object[213]	giv[213]	coref	32-11[236_213]
29-12	3993-3999	aortic	place|object[213]	giv|giv[213]	coref	32-12
29-13	4000-4004	wall	object[213]	giv[213]	_	_
29-14	4005-4010	which	_	_	_	_
29-15	4011-4022	contributes	_	_	_	_
29-16	4023-4025	to	_	_	_	_
29-17	4026-4033	elastin	substance	giv	_	_
29-18	4034-4037	and	_	_	_	_
29-19	4038-4046	collagen	organization|abstract[216]	giv|new[216]	_	_
29-20	4047-4056	synthesis	abstract[216]	new[216]	_	_
29-21	4057-4060	and	_	_	_	_
29-22	4061-4070	stability	abstract	new	_	_
29-23	4071-4072	.	_	_	_	_

#Text=Data from animal and human studies demonstrated that dietary Si mitigates the risk of cardiovascular diseases .
30-1	4073-4077	Data	abstract[218]	new[218]	_	_
30-2	4078-4082	from	abstract[218]	new[218]	_	_
30-3	4083-4089	animal	abstract[218]|animal	new[218]|new	_	_
30-4	4090-4093	and	abstract[218]	new[218]	_	_
30-5	4094-4099	human	abstract[218]|event[220]	new[218]|new[220]	_	_
30-6	4100-4107	studies	abstract[218]|event[220]	new[218]|new[220]	_	_
30-7	4108-4120	demonstrated	_	_	_	_
30-8	4121-4125	that	_	_	_	_
30-9	4126-4133	dietary	abstract|person[222]	new|giv[222]	coref|coref	31-1[0_222]|31-1[0_222]
30-10	4134-4136	Si	person[222]	giv[222]	_	_
30-11	4137-4146	mitigates	_	_	_	_
30-12	4147-4150	the	abstract[223]	new[223]	_	_
30-13	4151-4155	risk	abstract[223]	new[223]	_	_
30-14	4156-4158	of	abstract[223]	new[223]	_	_
30-15	4159-4173	cardiovascular	abstract[223]|abstract[224]	new[223]|new[224]	coref	31-14[230_224]
30-16	4174-4182	diseases	abstract[223]|abstract[224]	new[223]|new[224]	_	_
30-17	4183-4184	.	_	_	_	_

#Text=Si in drinking water has been inversely correlated with mortality rates due to coronary heart diseases in Finland .
31-1	4185-4187	Si	person	giv	coref	35-9
31-2	4188-4190	in	_	_	_	_
31-3	4191-4199	drinking	_	_	_	_
31-4	4200-4205	water	substance	new	_	_
31-5	4206-4209	has	_	_	_	_
31-6	4210-4214	been	_	_	_	_
31-7	4215-4224	inversely	_	_	_	_
31-8	4225-4235	correlated	_	_	_	_
31-9	4236-4240	with	_	_	_	_
31-10	4241-4250	mortality	abstract[227]	new[227]	_	_
31-11	4251-4256	rates	abstract[227]	new[227]	_	_
31-12	4257-4260	due	_	_	_	_
31-13	4261-4263	to	_	_	_	_
31-14	4264-4272	coronary	object|abstract[230]	new|giv[230]	_	_
31-15	4273-4278	heart	object|abstract[230]	new|giv[230]	_	_
31-16	4279-4287	diseases	abstract[230]	giv[230]	_	_
31-17	4288-4290	in	abstract[230]	giv[230]	_	_
31-18	4291-4298	Finland	abstract[230]|place	giv[230]|new	_	_
31-19	4299-4300	.	_	_	_	_

#Text=Reduced damage and thickening of elastic fibers were observed in the aortic wall after silicon supplementation in rabbit models of diet-induced atherosclerosis .
32-1	4301-4308	Reduced	abstract[232]	new[232]	_	_
32-2	4309-4315	damage	abstract[232]	new[232]	_	_
32-3	4316-4319	and	_	_	_	_
32-4	4320-4330	thickening	abstract[233]	giv[233]	_	_
32-5	4331-4333	of	abstract[233]	giv[233]	_	_
32-6	4334-4341	elastic	abstract[233]|object[234]	giv[233]|giv[234]	_	_
32-7	4342-4348	fibers	abstract[233]|object[234]	giv[233]|giv[234]	_	_
32-8	4349-4353	were	_	_	_	_
32-9	4354-4362	observed	_	_	_	_
32-10	4363-4365	in	_	_	_	_
32-11	4366-4369	the	object[236]	giv[236]	coref	38-6[278_236]
32-12	4370-4376	aortic	place|object[236]	giv|giv[236]	coref	39-9
32-13	4377-4381	wall	object[236]	giv[236]	_	_
32-14	4382-4387	after	_	_	_	_
32-15	4388-4395	silicon	substance|substance[238]	new|giv[238]	coref|coref|coref|coref	33-19[248_238]|33-21[249_0]|33-19[248_238]|33-21[249_0]
32-16	4396-4411	supplementation	substance[238]	giv[238]	_	_
32-17	4412-4414	in	substance[238]	giv[238]	_	_
32-18	4415-4421	rabbit	substance[238]|animal|abstract[240]	giv[238]|new|new[240]	_	_
32-19	4422-4428	models	substance[238]|abstract[240]	giv[238]|new[240]	_	_
32-20	4429-4431	of	substance[238]|abstract[240]	giv[238]|new[240]	_	_
32-21	4432-4444	diet-induced	substance[238]|abstract[240]|abstract[241]	giv[238]|new[240]|new[241]	_	_
32-22	4445-4460	atherosclerosis	substance[238]|abstract[240]|abstract[241]	giv[238]|new[240]|new[241]	_	_
32-23	4461-4462	.	_	_	_	_

#Text=Moreover , our results are in line with a previous study reporting reduction in systolic arterial pressure after supplementation with soluble silicon in SHR .
33-1	4463-4471	Moreover	_	_	_	_
33-2	4472-4473	,	_	_	_	_
33-3	4474-4477	our	person|abstract[243]	giv|giv[243]	ana|ana	35-6|35-6
33-4	4478-4485	results	abstract[243]	giv[243]	_	_
33-5	4486-4489	are	_	_	_	_
33-6	4490-4492	in	_	_	_	_
33-7	4493-4497	line	_	_	_	_
33-8	4498-4502	with	_	_	_	_
33-9	4503-4504	a	abstract[244]	giv[244]	coref	34-2[251_244]
33-10	4505-4513	previous	abstract[244]	giv[244]	_	_
33-11	4514-4519	study	abstract[244]	giv[244]	_	_
33-12	4520-4529	reporting	_	_	_	_
33-13	4530-4539	reduction	abstract	giv	_	_
33-14	4540-4542	in	_	_	_	_
33-15	4543-4551	systolic	person|abstract[247]	new|giv[247]	_	_
33-16	4552-4560	arterial	abstract[247]	giv[247]	_	_
33-17	4561-4569	pressure	abstract[247]	giv[247]	_	_
33-18	4570-4575	after	abstract[247]	giv[247]	_	_
33-19	4576-4591	supplementation	abstract[247]|substance[248]	giv[247]|giv[248]	coref	37-11[273_248]
33-20	4592-4596	with	abstract[247]|substance[248]	giv[247]|giv[248]	_	_
33-21	4597-4604	soluble	abstract[247]|substance[248]|substance[249]	giv[247]|giv[248]|giv[249]	_	_
33-22	4605-4612	silicon	abstract[247]|substance[248]|substance[249]	giv[247]|giv[248]|giv[249]	_	_
33-23	4613-4615	in	abstract[247]|substance[248]|substance[249]	giv[247]|giv[248]|giv[249]	_	_
33-24	4616-4619	SHR	abstract[247]|substance[248]|substance[249]|substance	giv[247]|giv[248]|giv[249]|giv	_	_
33-25	4620-4621	.	_	_	_	_

#Text=In that study , arterial structure was not investigated and enhancement of intracellular magnesium uptake was evoked as a possible mechanism .
34-1	4622-4624	In	_	_	_	_
34-2	4625-4629	that	abstract[251]	giv[251]	coref	37-7[271_251]
34-3	4630-4635	study	abstract[251]	giv[251]	_	_
34-4	4636-4637	,	_	_	_	_
34-5	4638-4646	arterial	abstract[252]	new[252]	_	_
34-6	4647-4656	structure	abstract[252]	new[252]	_	_
34-7	4657-4660	was	_	_	_	_
34-8	4661-4664	not	_	_	_	_
34-9	4665-4677	investigated	_	_	_	_
34-10	4678-4681	and	_	_	_	_
34-11	4682-4693	enhancement	abstract[253]	new[253]	_	_
34-12	4694-4696	of	abstract[253]	new[253]	_	_
34-13	4697-4710	intracellular	abstract[253]|abstract[255]	new[253]|new[255]	ana	35-1[0_255]
34-14	4711-4720	magnesium	abstract[253]|substance|abstract[255]	new[253]|new|new[255]	coref	35-30
34-15	4721-4727	uptake	abstract[253]|abstract[255]	new[253]|new[255]	_	_
34-16	4728-4731	was	_	_	_	_
34-17	4732-4738	evoked	_	_	_	_
34-18	4739-4741	as	_	_	_	_
34-19	4742-4743	a	_	_	_	_
34-20	4744-4752	possible	_	_	_	_
34-21	4753-4762	mechanism	_	_	_	_
34-22	4763-4764	.	_	_	_	_

#Text=This is not inconsistent with our findings as Si is supposed to contribute to biological function and affect retention or function of other minerals , such as aluminum or magnesium .
35-1	4765-4769	This	abstract	giv	_	_
35-2	4770-4772	is	_	_	_	_
35-3	4773-4776	not	_	_	_	_
35-4	4777-4789	inconsistent	_	_	_	_
35-5	4790-4794	with	_	_	_	_
35-6	4795-4798	our	person|abstract[258]	giv|new[258]	ana|ana	37-7|37-7
35-7	4799-4807	findings	abstract[258]	new[258]	_	_
35-8	4808-4810	as	_	_	_	_
35-9	4811-4813	Si	substance	giv	coref	36-11
35-10	4814-4816	is	_	_	_	_
35-11	4817-4825	supposed	_	_	_	_
35-12	4826-4828	to	_	_	_	_
35-13	4829-4839	contribute	_	_	_	_
35-14	4840-4842	to	_	_	_	_
35-15	4843-4853	biological	abstract[260]	giv[260]	_	_
35-16	4854-4862	function	abstract[260]	giv[260]	_	_
35-17	4863-4866	and	_	_	_	_
35-18	4867-4873	affect	_	_	_	_
35-19	4874-4883	retention	abstract	new	_	_
35-20	4884-4886	or	_	_	_	_
35-21	4887-4895	function	abstract[262]	new[262]	_	_
35-22	4896-4898	of	abstract[262]	new[262]	_	_
35-23	4899-4904	other	abstract[262]|substance[263]	new[262]|new[263]	_	_
35-24	4905-4913	minerals	abstract[262]|substance[263]	new[262]|new[263]	_	_
35-25	4914-4915	,	abstract[262]|substance[263]	new[262]|new[263]	_	_
35-26	4916-4920	such	abstract[262]|substance[263]	new[262]|new[263]	_	_
35-27	4921-4923	as	abstract[262]|substance[263]	new[262]|new[263]	_	_
35-28	4924-4932	aluminum	abstract[262]|substance[263]|substance	new[262]|new[263]|new	_	_
35-29	4933-4935	or	abstract[262]|substance[263]	new[262]|new[263]	_	_
35-30	4936-4945	magnesium	abstract[262]|substance[263]|substance	new[262]|new[263]|giv	_	_
35-31	4946-4947	.	_	_	_	_

#Text=Various mechanisms are potentially involved in the beneficial effects of Si .
36-1	4948-4955	Various	abstract[266]	new[266]	_	_
36-2	4956-4966	mechanisms	abstract[266]	new[266]	_	_
36-3	4967-4970	are	_	_	_	_
36-4	4971-4982	potentially	_	_	_	_
36-5	4983-4991	involved	_	_	_	_
36-6	4992-4994	in	_	_	_	_
36-7	4995-4998	the	abstract[267]	new[267]	_	_
36-8	4999-5009	beneficial	abstract[267]	new[267]	_	_
36-9	5010-5017	effects	abstract[267]	new[267]	_	_
36-10	5018-5020	of	abstract[267]	new[267]	_	_
36-11	5021-5023	Si	abstract[267]|substance	new[267]|giv	coref	39-5
36-12	5024-5025	.	_	_	_	_

#Text=Here , a major result in our study is that SpSi supplementation reverses elastic fiber degradation which is likely to contribute to the overall benefit .
37-1	5026-5030	Here	_	_	_	_
37-2	5031-5032	,	_	_	_	_
37-3	5033-5034	a	abstract[269]	giv[269]	_	_
37-4	5035-5040	major	abstract[269]	giv[269]	_	_
37-5	5041-5047	result	abstract[269]	giv[269]	_	_
37-6	5048-5050	in	abstract[269]	giv[269]	_	_
37-7	5051-5054	our	abstract[269]|person|abstract[271]	giv[269]|giv|giv[271]	_	_
37-8	5055-5060	study	abstract[269]|abstract[271]	giv[269]|giv[271]	_	_
37-9	5061-5063	is	_	_	_	_
37-10	5064-5068	that	_	_	_	_
37-11	5069-5073	SpSi	substance|substance[273]	giv|giv[273]	_	_
37-12	5074-5089	supplementation	substance[273]	giv[273]	_	_
37-13	5090-5098	reverses	_	_	_	_
37-14	5099-5106	elastic	abstract[275]	new[275]	_	_
37-15	5107-5112	fiber	substance|abstract[275]	giv|new[275]	_	_
37-16	5113-5124	degradation	abstract[275]	new[275]	_	_
37-17	5125-5130	which	_	_	_	_
37-18	5131-5133	is	_	_	_	_
37-19	5134-5140	likely	_	_	_	_
37-20	5141-5143	to	_	_	_	_
37-21	5144-5154	contribute	_	_	_	_
37-22	5155-5157	to	_	_	_	_
37-23	5158-5161	the	abstract[276]	giv[276]	_	_
37-24	5162-5169	overall	abstract[276]	giv[276]	_	_
37-25	5170-5177	benefit	abstract[276]	giv[276]	_	_
37-26	5178-5179	.	_	_	_	_

#Text=The observed regenerative changes of the vascular wall are in line with a Si-related beneficial effect .
38-1	5180-5183	The	abstract[277]	new[277]	_	_
38-2	5184-5192	observed	abstract[277]	new[277]	_	_
38-3	5193-5205	regenerative	abstract[277]	new[277]	_	_
38-4	5206-5213	changes	abstract[277]	new[277]	_	_
38-5	5214-5216	of	abstract[277]	new[277]	_	_
38-6	5217-5220	the	abstract[277]|object[278]	new[277]|giv[278]	_	_
38-7	5221-5229	vascular	abstract[277]|object[278]	new[277]|giv[278]	_	_
38-8	5230-5234	wall	abstract[277]|object[278]	new[277]|giv[278]	_	_
38-9	5235-5238	are	_	_	_	_
38-10	5239-5241	in	_	_	_	_
38-11	5242-5246	line	_	_	_	_
38-12	5247-5251	with	_	_	_	_
38-13	5252-5253	a	abstract[279]	giv[279]	_	_
38-14	5254-5264	Si-related	abstract[279]	giv[279]	_	_
38-15	5265-5275	beneficial	abstract[279]	giv[279]	_	_
38-16	5276-5282	effect	abstract[279]	giv[279]	_	_
38-17	5283-5284	.	_	_	_	_

#Text=However , quantification of Si level in the aortic tissue is warranted to validate this hypothesis .
39-1	5285-5292	However	_	_	_	_
39-2	5293-5294	,	_	_	_	_
39-3	5295-5309	quantification	abstract[280]	new[280]	_	_
39-4	5310-5312	of	abstract[280]	new[280]	_	_
39-5	5313-5315	Si	abstract[280]|person|abstract[282]	new[280]|giv|giv[282]	_	_
39-6	5316-5321	level	abstract[280]|abstract[282]	new[280]|giv[282]	_	_
39-7	5322-5324	in	abstract[280]|abstract[282]	new[280]|giv[282]	_	_
39-8	5325-5328	the	abstract[280]|abstract[282]|object[284]	new[280]|giv[282]|new[284]	_	_
39-9	5329-5335	aortic	abstract[280]|abstract[282]|abstract|object[284]	new[280]|giv[282]|giv|new[284]	_	_
39-10	5336-5342	tissue	abstract[280]|abstract[282]|object[284]	new[280]|giv[282]|new[284]	_	_
39-11	5343-5345	is	_	_	_	_
39-12	5346-5355	warranted	_	_	_	_
39-13	5356-5358	to	_	_	_	_
39-14	5359-5367	validate	_	_	_	_
39-15	5368-5372	this	abstract[285]	new[285]	_	_
39-16	5373-5383	hypothesis	abstract[285]	new[285]	_	_
39-17	5384-5385	.	_	_	_	_
